A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This thorough QT (TQT) study will take place in healthy subjects administered single doses of
study drug. It will be a randomized, double-blind, placebo and active-controlled, 4-treatment
crossover study. Subjects will be randomized in an equal ratio to one of 12 possible
treatment sequences. Each treatment sequence will comprise all 4 treatments.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination